Oftalamin®- Bioregulator of eyes.
Contributes to the normalization and improvement of functions of the different disorders, it is recommended when significant visual load.
Eye diseases and injuries of various etiologies are widespread among the population and represent a serious problem, since pretty much limited capacity of the patient, and often lead to disability. Traditional treatments of ophthalmic diseases do not always have a pathogenetic direction as often focused on general improvement trophics eyes. In this regard, in many cases the clinical effect is unstable, the pathological processes are progressing, which ultimately leads to blindness. For correction and prevention of pathological changes occurring in diseases of the eye, designed "Oftalamin."
Clinical trials of "Oftalamin" conducted in 198 patients with ophthalmic pathologies, including degenerative diseases of the retina of various etiologies and posttraumatic endothelial-epithelial corneal dystrophy.
The effectiveness of "Oftalamin" assessed by subjective and objective indicators. All the patients before and after treatment were examined by a comprehensive clinical program, including methods to assess the violation of visual functions, blood flow rate, the state of external and internal layers of the retina, the characterization of the retinal pigment epithelium. Studied sharpness and width of the visual fields, dark adaptation, intraocular pressure, biomicroscopy performed anterior segment and deep optical media stereooftalmoskopiya, direct ophthalmoscopy. Also used: vizokontrastometriyu, static and multiple central perimetry, color vision research and fluorescein angiography fundus.
In assessing clinical and physiological parameters in patients with degenerative diseases of the retina revealed changes in all departments of the eyeball (iris, lens, vitreous, optic nerve), indicating generalized pathological process with a tendency to progression.
The studies found that at course using "Oftalamin" maximum therapeutic effect was observed in patients with early degenerative changes of the retina, which was characterized by an increase in the severity and extension of the visual field (peripheral expansion of the boundaries, the reduction or disappearance of paracentral cattle).
The use of "Oftalamin" in post-traumatic disorders of the cornea help accelerate recovery of the integrity of the epithelial layer of the cornea and improve visual acuity. When uncomplicated recovery process in patients with complete recovery occurred with the disappearance of the phenomena of blepharospasm, photophobia, and the final formation of the corneal scar. The use of "Oftalamin" in the postoperative period in patients with partial destruction of the cornea thus avoiding infectious complications and achieve rapid and sustainable healing corneal transplant, reducing the time of treatment compared with standardized therapy schemes.
"Oftalamin" recommended for use in the adjuvant therapy to accelerate recovery of function in different tissues of the eye of their injuries, including the degenerative diseases of the retina, and post-traumatic dystrophy of the cornea, and the elderly to maintain the function of the organ of vision.
Indication of use:
1-3 tablets 2-3 times a day for 10-15 minutes before meals with water without chewing. Course: 10-14 days. Repeat the course in 3-6 months.
Individual intolerance to the product components, pregnancy, lactation.
40 tablets per pack